Patients whose tumor tissue had elevated expression of ATG5 exhibited a trend of higher risk of adverse clinical outcome compared to those with low expression, but without reaching statistical significance (HR [95 % CI]=1.43 [0.87-2.34], P=0.159 for OS, HR [95 % CI]=1.41 [0.88-2.27], P=0.150 for PFS, Table 4). The gene discussed is ATG5; the disease is neoplasm.